High dose barbiturates were used to treat intracranial hypertension in 15 patients with nontraumatic brain lesions; (3 hypertensive hemorrhage, 4 subarachnoid hemorrhage, 5 infarction, 2 global anoxia-ischemia and 1 encephalitis). All had persistently raised intracranial pressure (ICP) while being treated with aggressive conventional therapy. The addition of barbiturates caused an initial lowering of ICP in 11 patients, but only 5 of these had sustained ICP reductions. Survival of the 5 patients with persistently lowered ICP and death of the remaining 10 may indicate an improvement in outcome attributable to the addition of high dose barbiturates to conventional therapy in non-traumatic brain swelling. Because of the resources required for their prolonged use, randomized studies in patients with intracranial hypertension are required to determine the effect of barbiturates on outcome.
SUMMARY High dose barbiturates were used to treat intracranial hypertension in 15 patients with nontraumatic brain lesions; (3 hypertensive hemorrhage, 4 subarachnoid hemorrhage, 5 infarction, 2 global anoxia-ischemia and 1 encephalitis). All had persistently raised intracranial pressure (ICP) while being treated with aggressive conventional therapy. The addition of barbiturates caused an initial lowering of ICP in 11 patients, but only 5 of these had sustained ICP reductions. Survival of the 5 patients with persistently lowered ICP and death of the remaining 10 may indicate an improvement in outcome attributable to the addition of high dose barbiturates to conventional therapy in non-traumatic brain swelling. Because of the resources required for their prolonged use, randomized studies in patients with intracranial hypertension are required to determine the effect of barbiturates on outcome.
Stroke, Vol 13, No 6, 1982 BARBITURATES have been shown to reduce intracranial pressure (ICP) in normals, 1 to ameliorate the ICP rise which occurs during induction of anesthesia, 2 and to blunt the nocturnal rise in ICP associated with rapid eye movement sleep. 3 This has led to the investigational use of barbiturates in treatment of sustained elevations in ICP due to brain lesions. Satisfactory reduction in ICP with high dose barbiturates has been reported most frequently after head injury, and sporadically in encephalitis, cerebral hypoxia-ischemia, 4 ' 5 childhood drowning, and stroke. 4 A clear beneficial effect on outcome, however, has not been demonstrated. We therefore investigated the effect on outcome of high dose barbiturates in patients with nontraumatic brain lesions with elevated ICP.
Methods
Fifteen consecutive patients with non-traumatic intracranial hypertension whose ICP remained elevated, (> 15 mm Hg), despite conventional therapy were treated in a uniform manner with high dose barbiturates. Conventional therapy included osmotic diuresis with mannitol to maintain serum osmolarity greater than 300 mosm/1, positive pressure hyperventilation, control of elevated temperature with antipyretics and cooling blankets, and high dose steroids (dexamethasome 24-40 mg per day or solumedrol 320 mg per day, in divided doses). Surgical evacuation of hematomas and shunting of hydrocephalus were performed in appropriate circumstances. ICP was measured before and during barbiturate administration in all patients; 12 had subarachnoid screw devices and 3 had intraventricular catheters. Barbiturates were administered as soon as possible upon failure of standard therapy. Failure was defined as 15 to 30 minutes of sustained ICP greater than 15 mm Hg. Intravenous bolus pentobarbital (Nembutal) was used in doses of 50-300 mg/hr (1.5^1 mg/kg/hr). Several patients received loading doses of 4 mg/kg. Doses and intervals were modified according to ICP response and undesirable hypotension. Serum barbiturate levels were monitored in most patients and varied from 1-11.2 mg %. Barbiturate therapy was continued for at least 12 hours in all patients and discontinued under 3 circumstances: absence of any reduction in ICP after 2 consecutive doses of pentobarbital, reappearance of increased ICP at maximum tolerated pentobarbital doses after an initial response (defined as "escape"), or 48 consecutive hours of normal ICP, (less than 15 mm Hg).
Results
The patient's clinical characteristics and diagnoses are shown in table 1. Eleven were male and 4 female; mean age was 43 years. All 15 had decorticate or decerebrate posturing, 12 had third cranial nerve palsies, and 3 also had sixth cranial nerve palsies at the initiation of barbiturate therapy.
The mean duration of illness before pentobarbital was administered was 4.5 days, mean interval between failure of conventional therapy and use of pentobarbital, 2 hours, and mean ICP at the time of failure of conventional therapy, 31 mm Hg (table 2). Barbiturates were used for an average of 4 days. In 4 patients they were discontinued because 2 consecutive doses failed to reduce ICP to normal levels and in 6 there was an initial ICP response to barbiturates but failure of therapy 2 to 10 days later ("escape," table 2). The mean age of patients whose ICP was initially lowered by barbiturates ("good response" and "escape," 42 years) was not significantly different (t-test) from initial nonresponders (47 years).
Medical management pertaining to raised ICP is summarized in table 3. The levels listed represent the least desirable values which occurred during barbiturate therapy.
Only 5 of the 15 patients had a good ICP response to pentobarbital: 2 of the 7 with hemorrhage, 1 of the 5 with focal ischemia, 1 of the 2 with hypoxia and the single patient with encephalitis (table 2). Only those 5 patients who had a persistent lowering of ICP with barbiturate administration survived (table 4). The 2 surviving patients with severe disability required continued skilled nursing care. The 3 who became ambulatory were able to function at home with minimal assistance. Absence of an initial ICP response to barbiturate administration or transient response ("escape") Herpes simplex were associated in every case with death. The mean age of the 3 patients who became ambulatory (20 years) was significantly different from those who died (45 years, t = 2.98, df = 11, p > 0.05). Serum barbiturate concentrations during therapy in the 5 patients with good ICP responses were between 1.2-5.0 mg %. Concentrations at the time of discontinuation of barbiturates measured in 7 of the 10 patients with persistently elevated or escaped ICP were between 1.0-5.4 mg %. There was no significant difference in drug levels between patients who initially responded and non-responders, or in survivors, compared to non-survivors. Hypotension limited barbiturate doses in 9 of 10 patients who failed or escaped from barbiturate therapy and in all 5 who responded.
Discussion
Persistently elevated ICP has been associated with poor clinical outcome, particularly after head trauma. 6 ' 7 This association is underscored in raised ICP of non-traumatic origin by the deaths of all 10 of our 15 patients whose ICPs could not be lowered to the normal range. Although control of elevated ICP is attainable with standard therapy in most patients, 8 the addition of high dose barbiturates has been suggested for the group of patients whose ICPs remain elevated. Barbiturates initially lowered intractably elevated ICP in 11 of our 15 patients, although in 6, ICP subsequently returned to abnormal levels so that the number of patients who ultimately benefited from barbiturate administration was small. While it is not possible to know from this pilot study whether the ICP lowering effect of barbiturates resulted in an improvement in survival, the uniform mortality in patients with sustained elevation of ICP suggests that the few survivors might otherwise have died. Therefore, although bar-biturates succeeded in reducing elevated ICP unresponsive to standard therapy in only a minority of patients, those responding may have been salvaged by the addition of barbiturates. There was no significant difference in age between patients whose ICP was initially lowered by barbiturates and those not affected. Although the three ambulatory survivors were relatively younger than the remainder of the group, it cannot be determined from this small study if age is related to functional outcome.
The number of patients potentially benefiting from barbiturates in a clinical trial will depend to some extent on the nature of preceding conventional therapy. 8 This is especially true in the heterogeneous group of patients with non-traumatic brain swelling. Assiduous use of hyperosmolar agents, hyperventilation, steroids when indicated, and elimination of exacerbating factors such as fever will diminish the number of patients whose ICP cannot be controlled. This, in turn, reduces the number who will subsequently respond to the addition of barbiturates by selecting patients with severe brain swelling or large intracranial masses.
The substantial resources and potential risks associated with this therapy, as well as the diversity of pathology leading to brain swelling and the importance of vigorous conventional therapy in treating it, all underscore the need for further prospective and randomized studies before the use of barbiturates becomes indiscriminate and widespread. 8 The effects of high dose barbiturates on ICP should be considered separately from their putative ischemic protective effect.
